GuiZhou SanLi Pharmaceutical (603439.SS) Earnings Analysis
GuiZhou SanLi Pharmaceutical (603439.SS) has no confirmed upcoming earnings date. Trailing P/E 83.94.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does 603439.SS next report earnings?
No confirmed upcoming earnings date is currently scheduled for 603439.SS. This page updates as the calendar is published.
603439.SS earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2025-03-31 | 0.1 CNY | n/a | n/a | n/a |
| 2024-10-28 | 0.1895 CNY | n/a | n/a | n/a |
| 2024-08-28 | 0.15 CNY | n/a | n/a | n/a |
603439.SS valuation and analyst view
| Trailing P/E | 83.94 |
|---|---|
| Trailing EPS | 0.12067 CNY |
| Price / book | 2.73 |
| Dividend yield | 0.59% |
| Market cap | 3.98B |
Limited or no published sell-side analyst coverage for this symbol.
Related research pages
Frequently asked questions
When is GuiZhou SanLi Pharmaceutical (603439.SS)'s next earnings date?
No confirmed upcoming earnings date is currently scheduled for 603439.SS. This page updates as the calendar is published.
Did 603439.SS beat earnings last quarter?
Consensus estimate data was not available for 603439.SS's 2025-03-31 report.
What is 603439.SS's current P/E ratio and EPS?
603439.SS trades at a trailing P/E of 83.94 on trailing EPS of 0.12066884349443871 CNY.
What do analysts rate 603439.SS?
603439.SS has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.